Profitability
Weight: 25%
B+
79
- 5yr Avg ROIC 15.7%
- Operating Margin Trend +0.62 pp/yr
HALO
Halozyme Therapeutics, Inc.
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
Capital Efficiency
Weight: 15%
A+
97
- 5yr Avg ROE 286.1%
- 5yr Share-Count CAGR -2.6%
Growth Quality
Weight: 25%
A+
99
- 5yr Revenue CAGR 39.2%
- 5yr EPS CAGR 23.0%
- Revenue-Growth Years (5) 5/5
Cash Generation
Weight: 20%
A+
98
- 5yr FCF Margin 48.0%
- 5yr FCF/NI Conversion 1.26x
Balance Sheet
Weight: 10%
B
73
- Net Debt / EBITDA 3.49x
- Interest Coverage (EBIT/Int) 26.76x
- Altman Z-Score 4.64
Stability
Weight: 5%
C
54
- EPS Volatility (σ/μ) 0.55
- Negative-Revenue Years (5) 0/5
- Piotroski F-Score 5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.3 of 3 gurus held; 1 added; 2 trimmed.
- Holders
- 3
- Avg Δ position
- +8.2%
- New buys
- 0
- Full exits
- 0
- Cooperman increased +35%
- Dalio decreased -9%
- Greenblatt decreased -1%